Literature DB >> 23545208

Streptozotocin-induced diabetes affects the development and maintenance of morphine reward in rats.

Razieh Samandari1, Atieh Chizari, Rezvan Hassanpour, Zahra Mousavi, Abbas Haghparast.   

Abstract

Diabetes mellitus is a chronic illness that has been associated with the decrease of insulin in type I diabetes. Insulin has an impact not only on the direct control of food intake and plasma glucose levels, but also on brain pathways associated with reward. It affects brain reward pathways through regulation of the dopamine (DA) transporter (DAT). Moreover, it has been found to affect the ability of drugs that target the DA system. In the present study, the effects of streptozotocin (STZ)-induced diabetes on the acquisition (development) and maintenance of morphine-induced conditioned place preference (CPP) were investigated in rats. Forty adult male Albino Wistar rats were used in these experiments. For induction of diabetes, STZ was administered at a dose of 60 mg/kg. After seven days, the CPP paradigm was done; conditioning score and locomotor activity were recorded by Ethovision software. The results showed that diabetes significantly increased the magnitude of conditioning scores, acquisition of morphine-induced CPP in compared to naive animals (P<0.05). Moreover, in the diabetic group, there were significant differences among conditioning scores in the post-conditioning phase and the last four days (7th-10th), but these differences elongated up to 10 days after the CPP protocol while the extinction period was eight days in the naive group. Our findings indicated that the magnitude and maintenance of morphine rewarding properties have been changed in STZ-induced diabetic animals. It seems that a level of insulin and their receptors are involved in the development and maintenance of morphine-induced CPP in the rats.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23545208     DOI: 10.1016/j.neulet.2013.03.024

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

Review 1.  The hormonal signature of energy deficit: Increasing the value of food reward.

Authors:  Sarah H Lockie; Zane B Andrews
Journal:  Mol Metab       Date:  2013-08-19       Impact factor: 7.422

2.  Compensatory Role of Insulin in the Extinction but Not Reinstatement of Morphine-Induced Conditioned Place Preference in the Streptozotocin-Induced Diabetic Rats.

Authors:  Atieh Chizari; Rezvan Hassanpour; Saeideh Karimi-Haghighi; Ronak Azizbeigi; Somaye Mesgar; Zahra Mousavi; Abbas Haghparast
Journal:  Neurochem Res       Date:  2022-02-21       Impact factor: 3.996

3.  Morphine-induced apoptosis in the ventral tegmental area and hippocampus after the development but not extinction of reward-related behaviors in rats.

Authors:  Yasaman Razavi; Shabnam Zeighamy Alamdary; Seyedeh-Najmeh Katebi; Fariba Khodagholi; Abbas Haghparast
Journal:  Cell Mol Neurobiol       Date:  2013-11-27       Impact factor: 5.046

4.  Insulin modulates the strong reinforcing effects of nicotine and changes in insulin biomarkers in a rodent model of diabetes.

Authors:  Bryan Cruz; Rodolfo J Flores; Kevin P Uribe; Evangelina J Espinoza; Charles T Spencer; Katherine M Serafine; Arbi Nazarian; Laura E O'Dell
Journal:  Neuropsychopharmacology       Date:  2019-01-07       Impact factor: 7.853

5.  In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator.

Authors:  Prabhat Singh; Bhupesh Sharma; Surbhi Gupta; B M Sharma
Journal:  Psychopharmacology (Berl)       Date:  2014-07-26       Impact factor: 4.530

6.  Evoked hypoalgesia is accompanied by tonic pain and immune cell infiltration in the dorsal root ganglia at late stages of diabetic neuropathy in mice.

Authors:  Nitin Agarwal; Johanna Helmstädter; Daniel R Rojas; Kiran K Bali; Vijayan Gangadharan; Rohini Kuner
Journal:  Mol Pain       Date:  2018-11-20       Impact factor: 3.395

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.